Cardiorenal Syndrome: An Overview

  • Claudio Ronco
    International Renal Research Institute, S. Bortolo Hospital, Vicenza, Italy; Department of Nephrology and Dialysis, ASST Lariana, S. Anna Hospital, Como, Italy; and Department of Nephrology and Dialysis, L. Parodi - Delfino Hospital, Colleferro, Italy
    Search for articles by this author
  • Antonio Bellasi
    International Renal Research Institute, S. Bortolo Hospital, Vicenza, Italy; Department of Nephrology and Dialysis, ASST Lariana, S. Anna Hospital, Como, Italy; and Department of Nephrology and Dialysis, L. Parodi - Delfino Hospital, Colleferro, Italy
    Search for articles by this author
  • Luca Di Lullo
    Address correspondence to Luca Di Lullo, MD, PhD, Department of Nephrology and Dialysis L. Parodi - Delfino Hospital, Piazza Aldo Moro, 1-00034 Colleferro, Roma, Italy.
    International Renal Research Institute, S. Bortolo Hospital, Vicenza, Italy; Department of Nephrology and Dialysis, ASST Lariana, S. Anna Hospital, Como, Italy; and Department of Nephrology and Dialysis, L. Parodi - Delfino Hospital, Colleferro, Italy
    Search for articles by this author
      It is well established that a large number of patients with acute decompensated heart failure present with various degrees of heart and kidney dysfunction usually primary disease of heart or kidney often involve dysfunction or injury to the other. The term cardiorenal syndrome increasingly had been used without a consistent or well-accepted definition. To include the vast array of interrelated derangements and to stress the bidirectional nature of heart-kidney interactions, a new classification of the cardiorenal syndrome with 5 subtypes that reflect the pathophysiology, the time frame, and the nature of concomitant cardiac and renal dysfunction was proposed. Cardiorenal syndrome can generally be defined as a pathophysiological disorder of the heart and kidneys, in which acute or chronic dysfunction of one organ may induce acute or chronic dysfunction to the other. Although cardiorenal syndrome was usually referred to as acute kidney dysfunction following acute cardiac disease, it is now clearly established that impaired kidney function can have an adverse impact on cardiac function.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ronco C.
        The cardiorenal syndrome: basis and common ground for a multidisciplinary patient-oriented therapy.
        Cardiorenal Med. 2011; 1: 3-4
        • Ronco C.
        • House A.A.
        • Haapio M.
        Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong.
        Intensive Care Med. 2008; 34: 957-962
        • Hillege H.L.
        • Girbes A.R.J.
        • de Kam P.J.
        • et al.
        Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
        Circulation. 2000; 102: 203-210
        • Giam B.
        • Kaye D.M.
        • Rajapakse N.W.
        Role of renal oxidative stress in the pathogenesis of the cardiorenal syndrome.
        Heart Lung Circ. 2016; 25: 874-880
        • Iwata K.
        • Matsuno K.
        • Murata A.
        • et al.
        Up-regulation of NOX1/NADPH oxidase following drug-induced myocardial injury promotes cardiac dysfunction and fibrosis.
        Free Radic Biol Med. 2018; 120: 277-288
        • Buggey J.
        • Mentz R.J.
        • DeVore A.D.
        • Velazquez E.J.
        Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
        J Card Fail. 2015; 21: 741-750
        • Martinez B.K.
        • White C.M.
        The emerging role of inflammation in cardiovascular disease.
        Ann Pharmacother. 2018; 52: 801-809
        • Senni M.
        • D'Elia E.
        • Emdin M.
        • Vergaro G.
        Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction.
        in: Bauersachs J. Butler J. Marsh N. Heart Failure. Springer International Publishing, Cham, Switzerland2016: 79-108
        • Travessa A.M.
        • Menezes Falcão L.
        Vasodilators in acute heart failure—evidence based on new studies.
        Eur J Intern Med. 2018; 51: 1-10
        • Bagshaw S.M.
        • Cruz D.N.
        • Aspromonte N.
        • et al.
        Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference.
        Nephrol Dial Transplant. 2010; 25: 1406-1416
        • Damman K.
        • Navis G.
        • Voors A.A.
        • et al.
        Worsening renal function and prognosis in heart failure: systematic review and meta-analysis.
        J Card Fail. 2007; 13: 599-608
        • McCullough P.A.
        Cardiorenal syndromes: pathophysiology to prevention.
        Int J Nephrol. 2010; 2011: 762590
        • Ronco C.
        • Cicoira M.
        • McCullough P.A.
        Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure.
        J Am Coll Cardiol. 2012; 60: 1031-1042
        • Stevenson L.W.
        The limited reliability of physical signs for estimating hemodynamics in chronic heart failure.
        JAMA. 1989; 261: 884-888
        • Mullens W.
        • Abrahams Z.
        • Francis G.S.
        • et al.
        Importance of venous congestion for worsening of renal function in advanced decompensated heart failure.
        J Am Coll Cardiol. 2009; 53: 589-596
        • Uthoff H.
        • Breidthardt T.
        • Klima T.
        • et al.
        Central venous pressure and impaired renal function in patients with acute heart failure.
        Eur J Heart Fail. 2011; 13: 432-439
        • Braam B.
        • Cupples W.A.
        • Joles J.A.
        • Gaillard C.
        Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure.
        Heart Fail Rev. 2012; 17: 161-175
        • Han W.K.
        • Bonventre J.V.
        Biologic markers for the early detection of acute kidney injury.
        Curr Opin Crit Care. 2004; 10: 476-482
        • Hekmat R.
        • Mohebi M.
        Comparison of serum creatinine, cystatin C, and neutrophil gelatinase-associated lipocalin for acute kidney injury occurrence according to risk, injury, failure, loss, and end-stage criteria classification system in early after living kidney donation.
        Saudi J Kidney Dis Transpl. 2016; 27: 659-664
        • Vaidya V.S.
        • Ramirez V.
        • Ichimura T.
        • Bobadilla N.A.
        • Bonventre J.V.
        Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury.
        Am J Physiol Renal Physiol. 2006; 290: F517-F529
        • Di Lullo L.
        • Floccari F.
        • Granata A.
        • et al.
        Ultrasonography: Ariadne's thread in the diagnosis of the cardiorenal syndrome.
        Cardiorenal Med. 2012; 2: 11-17
        • Hebert K.
        • Dias A.
        • Delgado M.C.
        • et al.
        Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population.
        Eur J Heart Fail. 2010; 12: 861-865
        • Heywood J.T.
        • Fonarow G.C.
        • Costanzo M.R.
        • Mathur V.S.
        • Wigneswaran J.R.
        • Wynne J.
        High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database.
        J Card Fail. 2007; 13: 422-430
        • Cruz D.N.
        • Bagshaw S.M.
        Heart-kidney interaction: epidemiology of cardiorenal syndromes.
        Int J Nephrol. 2010; 2011: 351291
        • Palazzuoli A.
        • Silverberg D.S.
        • Iovine F.
        • et al.
        Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
        Am Heart J. 2007; 154: 645.e9-645.e15
        • Nohria A.
        • Hasselblad V.
        • Stebbins A.
        • et al.
        Cardiorenal interactions: insights from the ESCAPE trial.
        J Am Coll Cardiol. 2008; 51: 1268-1274
        • Jie K.E.
        • Verhaar M.C.
        • Cramer M.-J.M.
        • et al.
        Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors.
        Am J Physiol Renal Physiol. 2006; 291: F932-F944
        • Swedberg K.
        • Young J.B.
        • Anand I.S.
        • et al.
        Treatment of anemia with darbepoetin alfa in systolic heart failure.
        N Engl J Med. 2013; 368: 1210-1219
        • Kingma Jr., J.G.
        • Vincent C.
        • Rouleau J.R.
        • Kingma I.
        Influence of acute renal failure on coronary vasoregulation in dogs.
        J Am Soc Nephrol. 2006; 17: 1316-1324
        • Prabhu S.D.
        Cytokine-induced modulation of cardiac function.
        Circ Res. 2004; 95: 1140-1153
        • Ali T.
        • Khan I.
        • Simpson W.
        • et al.
        Incidence and outcomes in acute kidney injury: a comprehensive population-based study.
        J Am Soc Nephrol. 2007; 18: 1292-1298
        • Liano F.
        • Pascual J.
        Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group.
        Kidney Int. 1996; 50: 811-818
        • Liano F.
        • Junco E.
        • Pascual J.
        • Madero R.
        • Verde E.
        The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group.
        Kidney Int Suppl. 1998; 66: S16-S24
        • de Abreu K.L.S.
        • Júnior G.B.S.
        • Barreto A.G.
        • et al.
        Acute kidney injury after trauma: prevalence, clinical characteristics and RIFLE classification.
        Indian J Crit Care Med. 2010; 14: 121-128
        • Bongartz L.G.
        • Cramer M.J.
        • Doevendans P.A.
        • Joles J.A.
        • Braam B.
        The severe cardiorenal syndrome: ‘Guyton revisited’.
        Eur Heart J. 2004; 26: 11-17
        • Scheuer J.
        The effects of uremic compounds on cardiac function and metabolism.
        J Mol Cell Cardiol. 1973; 5: 287-300
        • Ozmen C.A.
        • Akin D.
        • Bilek S.U.
        • Bayrak A.H.
        • Senturk S.
        • Nazaroglu H.
        Ultrasound as a diagnostic tool to differentiate acute from chronic renal failure.
        Clin Nephrol. 2010; 74: 46-52
        • Licurse A.
        • Kim M.C.
        • Dziura J.
        • et al.
        Renal ultrasonography in the evaluation of acute kidney injury.
        Arch Intern Med. 2010; 170: 1900-1907
        • Picano E.
        • Frassi F.
        • Gligorova S.
        • Gargani L.
        • Mottola G.
        Ultrasound lung comets: a clinically useful sign of extravascular lung water.
        J Am Soc Echocardiogr. 2006; 19: 356-363
        • Chuasuwan A.
        • Kellum J.A.
        Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment.
        Semin Nephrol. 2012; 32: 31-39
        • Go A.S.
        • Chertow G.M.
        • Fan D.
        • McCulloch C.E.
        • Hsu C.-Y.
        Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
        N Engl J Med. 2004; 351: 1296-1305
        • United States Renal Data System
        USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States.
        National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD2009
        • Olgaard K.
        • Lewin E.
        • Silver J.
        Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD.
        Nephrol Dial Transplant. 2011; 26: 1117-1119
        • MacRae J.M.
        • Pandeya S.
        • Humen D.P.
        • Krivitski N.
        • Lindsay R.M.
        Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms.
        Am J Kidney Dis. 2004; 43: e17-e22
        • Cianciolo G.
        • De Pascalis A.
        • Di Lullo L.
        • Ronco C.
        • Zannini C.
        • La Manna G.
        Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: which comes first?.
        Cardiorenal Med. 2017; 7: 255-266
        • Bellasi A.
        • Di Lullo L.
        • Di Iorio B.
        Vascular inflammation: a call for a specific and sensitive biomarker?.
        Atherosclerosis. 2018; 271: 235-236
        • Di Lullo L.
        • Rivera R.
        • Barbera V.
        • et al.
        Sudden cardiac death and chronic kidney disease: from pathophysiology to treatment strategies.
        Int J Cardiol. 2016; 217: 16-27
        • Di Lullo L.
        • Ronco C.
        • Cozzolino M.
        • et al.
        Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
        Thromb Res. 2017; 155: 38-47
        • Austin W.J.
        • Bhalla V.
        • Hernandez-Arce I.
        • et al.
        Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease.
        Am J Clin Pathol. 2006; 126: 506-512
        • Ronco C.
        • Di Lullo L.
        Cardiorenal syndrome.
        Heart Fail Clin. 2014; 10: 251-280
        • Ricci Z.
        • Ronco C.
        Pathogenesis of acute kidney injury during sepsis.
        Curr Drug Targets. 2009; 10: 1179-1183
        • Li X.
        • Hassoun H.T.
        • Santora R.
        • Rabb H.
        Organ crosstalk: the role of the kidney.
        Curr Opin Crit Care. 2009; 15: 481-487
        • Virzì G.M.
        • Clementi A.
        • Brocca A.
        • de Cal M.
        • Ronco C.
        Molecular and genetic mechanisms involved in the pathogenesis of cardiorenal cross talk.
        Pathobiology. 2016; 83: 201-210
        • Merx M.W.
        • Weber C.
        Sepsis and the heart.
        Circulation. 2007; 116: 793-802
        • Reines H.D.
        • Halushka P.V.
        • Cook J.A.
        • Wise W.C.
        • Rambo W.
        Plasma thromboxane concentrations are raised in patients dying with septic shock.
        Lancet. 1982; 2: 174-175
        • Rangel-Frausto M.S.
        • Pittet D.
        • Costigan M.
        • Hwang T.
        • Davis C.S.
        • Wenzel R.P.
        The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study.
        JAMA. 1995; 273: 117-123
        • Badr K.F.
        • Kelley V.E.
        • Rennke H.G.
        • Brenner B.M.
        Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure.
        Kidney Int. 1986; 30: 474-480
        • Kikeri D.
        • Pennell J.P.
        • Hwang K.H.
        • Jacob A.I.
        • Richman A.V.
        • Bourgoignie J.J.
        Endotoxemic acute renal failure in awake rats.
        Am J Physiol. 1986; 250: F1098-F1106
        • Reinhart K.
        • Bauer M.
        • Riedemann N.C.
        • Hartog C.S.
        New approaches to sepsis: molecular diagnostics and biomarkers.
        Clin Microbiol Rev. 2012; 25: 609-634
        • Vignon P.
        • Frank M.B.
        • Lesage J.
        • et al.
        Hand-held echocardiography with Doppler capability for the assessment of critically-ill patients: is it reliable?.
        Intensive Care Med. 2004; 30: 718-723
        • Kellum J.A.
        • Lameire N.
        • Aspelin P.
        • et al.
        Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury.
        Kidney Int Suppl. 2012; 2: 1-138